An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Lantheus to Present at the Jefferies London Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Lantheus Holdings, Inc. (NASDAQ: LNTH) announces participation in Jefferies London Healthcare Conference. Paul Blanchfield, President, and Bob Marshall, CFO, to present at 8:00 a.m. GMT on November 15. Webcast available on company website.
Positive
None.
Negative
None.
BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes,, today announced Paul Blanchfield, President, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies London Healthcare Conference at 8:00 a.m. GMT (3 a.m. EST) on Wednesday, November 15.
To access a live webcast of the presentation, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcast will be available on the Company’s website for at least 30 days following the live presentation.
About Lantheus Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.
Contacts: Mark Kinarney Vice President, Investor Relations 978-671-8842 ir@lantheus.com
What is the latest announcement from Lantheus Holdings, Inc. (LNTH)?
Lantheus Holdings, Inc. (LNTH) announced its participation in the Jefferies London Healthcare Conference with its President and CFO presenting at the event.
When and where will the presentation take place?
The presentation will take place at 8:00 a.m. GMT on November 15 at the Jefferies London Healthcare Conference. A live webcast will be available on the company's website.
How can I access the webcast of the presentation?
To access the live webcast of the presentation, visit the Investors section of Lantheus Holdings, Inc.'s website at www.lantheus.com. A replay will also be available for at least 30 days following the live presentation.
lantheus holdings, inc. (nasdaq: lnth) is the parent company of lantheus medical imaging, inc. (lmi), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. lmi provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. lmi’s key products include the echocardiography contrast agent definity® vial for (perflutren lipid microsphere) injectable suspension; technelite® (technetium tc99m generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and xenon (xenon xe 133 gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. the company is headquartered in north billerica, massachusetts with offices in puerto rico and canada. for more information, visit www.lantheus.com.
